Biotech Firms Advance BLA Pathways with Key Clinical Milestones
Diamyd Medical anticipates March 2026 interim results from its Phase 3 diabetes trial that could support a BLA pathway. Capricor Therapeutics awaits an August 2026 FDA decision on its Duchenne muscular dystrophy treatment BLA. Bicara Therapeutics prepares for Phase 3 study initiation of its oncology candidate toward future BLA submission.
Three biotechnology companies are progressing toward potential Biologics License Application (BLA) submissions with key clinical trial milestones and regulatory reviews underway. Diamyd Medical has fully enrolled its pivotal Phase 3 trial DIAGNODE-3 with an interim efficacy readout anticipated on March 27, 2026, while Capricor Therapeutics awaits an FDA decision on its BLA with a target action date of August 22, 2026, and Bicara Therapeutics prepares for Phase 3 pivotal study initiation for its lead candidate.
Diamyd Medical's Phase 3 trial DIAGNODE-3 has randomized 321 patients across 57 clinical sites in Europe and the United States. The upcoming interim analysis evaluates preservation of C-peptide from baseline to month 15 in a genetically defined patient population representing approximately 40 percent of individuals with type 1 diabetes in Europe and the United States. Should the interim analysis demonstrate statistically significant efficacy, the results may support further regulatory interactions with the FDA regarding the potential BLA pathway in the United States. The trial continues with follow-up of all participants toward the full study readout expected in the third quarter of 2027, intended to support a potential BLA for full approval.
The company recently entered into directed equity financing agreements with new U.S. sector specialist investors, raising approximately USD 25 million before transaction costs. In addition, the newly issued warrants may provide an additional USD 100 million upon full exercise. Together with existing warrants, this establishes a total potential financing capacity of around USD 160 million. For the quarter ending February 28, 2026, Diamyd Medical reported net sales of MSEK 0.3 and a net result of MSEK -111.7, with cash and short-term investments of MSEK 190.7.
Capricor Therapeutics reported a fourth quarter 2025 non-GAAP earnings per share loss of $0.62, which fell short of analyst estimates of a $0.55 loss. The company reported no revenue for the quarter. The Biologics License Application for its lead candidate deramiocel (CAP-1002) for the treatment of Duchenne muscular dystrophy is currently under review by the FDA, with a Prescription Drug User Fee Act target action date set for August 22, 2026. The company's pivotal HOPE-3 Phase 3 trial for deramiocel achieved its primary and secondary endpoints, providing the clinical foundation for the BLA submission.
For the full year 2026, analysts are modeling revenue of $106.5 million and an EPS of -$1.57 for Capricor. For the upcoming first quarter of 2026, estimates point to revenue of $0.0 million and an EPS of -$0.48.
Bicara Therapeutics, which completed its initial public offering in September 2024 raising approximately $362 million, is developing bifunctional antibodies for oncology. The company's lead candidate ficerafusp alfa is a bifunctional antibody targeting EGFR and TGF-β currently in Phase 1/2 clinical trials for head and neck squamous cell carcinoma. In 2024, the FDA granted Breakthrough Therapy Designation to ficerafusp alfa based on promising tumor response rates. Key events to watch in 2025 include the initiation of the Phase 3 pivotal study for ficerafusp alfa, with success in these trials being essential for the company to move toward a BLA. The company reported sufficient cash reserves to fund operations into 2026.